

NEW/EXEMPT

Principal Investigator:	Wycoff, Kirby	Date of Exemption:	09/22/2026
Department:	Jefferson College of Health Professions	Annual Check-In Due:	07/22/2027
Sponsor:	Jefferson	Meeting Date:	10/15/2026
Level of Review:	Exempt	Review Board:	Chambers Board #2405
Risk Level:	Not Greater than Minimal Risk under 45 CFR 46 / 21 CFR 56	IRB#:	iRISID-2026-1130
Title:	Preclinical medical students' descriptions of the influence of palliative care education on their understanding of palliative care		

September 22, 2026

Dear Dr. Wycoff:

The **Institutional Review Board (IRB)** has reviewed the involvement of humans as research participants in your study.

In accordance with Federal-Wide Assurance #00002109 to the U.S. Department of Health and Human Services, your study was determined to be **EXEMPT** from IRB review on **09/22/2026** pursuant to Title 45 *Code of Federal Regulations* Part 46.104(d) governing exempt categories of research.

The following exempt determination has been made **per 45 CFR 46.104(d)**:

Exemption Categories Applied:	Category 2: Research Involving Educational Tests, Surveys, Interviews, Observation of Public Behavior
--------------------------------------	--

Any proposed changes in the protocol, study application, study materials, principal investigator, or in the written consent form must be submitted in iRIS via an **Amendment to Research Protocol** form for IRB for review and approval before the proposed changes can be implemented.

Please submit the Annual Check-in Form for Exempt and No Further Continuing Review Studies every year that the study is active as well as at time of study closure. You will receive reminders from iRIS notifying you when these are due.

This approval verifies that the IRB operates in accordance with applicable federal, local and institutional regulations that govern IRB operations.

Stamped informed consent forms and other documents, if applicable, can be accessed under the Protocol Items in the submissions tab in the IRIS Study Record.

If you have any questions or concerns regarding this transaction, please contact the assigned analyst: Latesh Boyd.

